Balchem Corp (BCPC)

Balchem Corp. has reported strong financial results, including record first-quarter consolidated sales, adjusted EBITDA, adjusted net earnings, and adjusted EPS for Q1 2026. Net sales for Q1 2026 were $270.7 million, an 8.1% increase year-over-year, with GAAP net earnings of $40.3 million and adjusted EBITDA of $74.3 million. For the full year 2025, Balchem reported record sales of $1.037 billion and record adjusted EBITDA of $274.9 million, and increased its dividend by a double-digit percentage. Management has cautioned about potential supply chain disruptions and modest margin compression due to geopolitical conflicts and petrochemical-based inflation. Balchem announced a global price increase across its Animal Nutrition and Health product portfolio, effective April 15, 2026, to address increased costs. BCPC's stock price has seen a 5.66% increase over the past six months, with a share price of $175.17 as of April 22, 2026.

Balchem's demand appears to be relatively stable across its diverse end markets, with healthy demand across the vast majority of its markets, particularly in Human Nutrition & Health. The company's revenue is well-distributed across human health, animal health, and medical sterilization industries. The Animal Nutrition & Health segment benefits from ruminant and monogastric market gains, with international markets growing faster than the U.S. The Specialty Products segment's growth has been driven by Performance Gases and geographic expansion in Plant Nutrition. Consumer shifts towards preventative healthcare are also driving higher demand for choline and Vitamin K2. While the overall demand backdrop is stable, the company has noted that the animal nutrition industry can be subject to volatility in milk and feed prices, and ongoing geopolitical conflicts have led to increased costs.

Balchem Corporation is a global specialty chemicals and nutrition company that develops, manufactures, distributes, and markets specialty performance ingredients and products across various industries. The company operates within the Basic Materials sector, specifically in the Specialty Chemicals industry, focusing on high-value, low-volume ingredients. Balchem's operations are divided into three primary business segments: Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides customized food and beverage ingredient systems and key nutrients. The ANH segment offers nutritional products for various animal health markets. The Specialty Products segment repackages and distributes performance gases and chemicals and provides chelated minerals to the agricultural market.

Balchem has a global presence with its corporate headquarters in Montvale, New Jersey, USA. The company maintains a broad network of manufacturing sites, regional offices, and technology centers primarily located in the U.S. and Europe. Manufacturing sites are located in various U.S. states and international locations including Canada, Italy, Belgium, Malaysia, and Norway. Regional offices are situated in the Netherlands, Belgium, Germany, USA, Italy, and Norway. Technology centers are found in Italy, USA, and Norway. North America accounts for approximately 75% of its revenue, with the 2022 acquisition of Kappa Bioscience expanding its access to EMEA markets.

Balchem has maintained a positive brand reputation, particularly in corporate social responsibility. Balchem was named on Newsweek's 2024 list of America's Most Responsible Companies for the fourth consecutive year and released its fifth Sustainability Report in 2023, highlighting progress towards its 2030 goals. Recent scientific research using Balchem's VitaCholine® ingredient indicated that choline may enhance brain network efficiency in post-menopausal women. The company also engages in marketing partnerships to increase awareness and adoption of its VitaCholine and K2VITAL brands.

Balchem Corp. stock ownership is primarily institutional, with institutional shareholders holding approximately 89.24% of the company's stock, 2.45% held by Balchem insiders, and 8.32% by retail investors. Major institutional owners include BlackRock Inc., Vanguard Group Inc., and State Street Corp.